US Patent No: 6,258,360

Number of patents in Portfolio can not be more than 2000

Prodrugs activated by targeted catalytic proteins

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PROTEINIX, INC.GAITHERSBURG, MD38
WELLSTAT BIOCATALYSIS, LLCGAITHERSBURG, MD42

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Casadei, Jan M Bethesda, MD 4 5
Kamireddy, Balreddy Rockville, MD 14 28
Kenten, John Henry Gaithersburg, MD 6 49
Martin, Mark T Rockville, MD 41 334
Massey, Richard J Rockville, MD 48 708
Napper, Andrew D Hopkinton, MA 11 44
Simpson, David M Adelphi, MD 17 86
Smith, Rodger G Jefferson, MD 16 49
Titmas, Richard C 12905 Crookston La., Apt. 103, Rockville, MD 20851 14 36
Von, Borstel Reid Potomac, MD 8 42
Williams, Richard O London, GB2 10 114

Cited Art

Patent Info (Count) # Cites Year
 
WELLSTAT BIOCATALYSIS, LLC (3)
4,888,281 Method of catalyzing chemical reactions 42 1984
4,792,446 Production of antibody catalysts 43 1986
4,963,355 Production of antibody catalysts 25 1987
 
HYBRITECH INCORPORATED (2)
4,376,110 Immunometric assays using monoclonal antibodies 682 1980
4,486,530 Immunometric assays using monoclonal antibodies 197 1981
 
MILES LABORATORIES, INC. (2)
4,492,751 Heterogenous specific binding assay employing an enzyme substrate as label 36 1979
4,493,890 Activated apoglucose oxidase and its use in specific binding assays 52 1982
 
THE SCRIPPS RESEARCH INSTITUTE (2)
4,659,567 Molecules with antibody combining sites that bind to hydrolytic transition states 38 1984
4,900,674 Antibody combining sites that exhibit amide or ester synthase activity 25 1987
 
BRISTOL-MYERS COMPANY (1)
4,975,278 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells 177 1988
 
BRISTOL-MYERS SQUIBB PHARMA COMPANY (1)
4,668,685 Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists 13 1985
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,757,062 Substituted benzoate ester prodrugs of estrogens 2 1985
 
HOFFMANN-LA ROCHE INC. (1)
4,966,891 Fluorocytidine derivatives 31 1988
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,211,773 5-Substituted 1-(2'-Deoxy-2'-substituted-.beta.-D-arabinofuranosyl)pyrimidine nucleosides 50 1978
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,661,586 Monoclonal anti-idiotype antibodies 28 1983
 
THE WISTAR INSTITUTE (1)
4,196,265 Method of producing antibodies 243 1978
 
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (1)
5,411,984 Water soluble analogs and prodrugs of taxol 14 1992

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
BEHRINWERKE AKTIENGESELLSCHAFT (2)
7,060,495 Fusion proteins for prodrug activation 1 1997
7,273,727 Fusion proteins for prodrug activation 0 2005

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 10, 2013
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00